TITLE:

Roles of linear ubiquitinylation, a crucial regulator of NF- κ B and cell death, in the immune system.

AUTHOR(S):

Sasaki, Katsuhiro; Iwai, Kazuhiro

CITATION:

Sasaki, Katsuhiro ...[et al]. Roles of linear ubiquitinylation, a crucial regulator of NF- κ B and cell death, in the immune system.. Immunological reviews 2015, 266(1): 175-189

ISSUE DATE:

2015-06-18

URL:

<http://hdl.handle.net/2433/201880>

RIGHT:

This is the peer reviewed version of the following article: Sasaki, K. and Iwai, K. (2015), Roles of linear ubiquitinylation, a crucial regulator of NF- κ B and cell death, in the immune system. Immunological Reviews, 266: 175-189, which has been published in final form at <http://dx.doi.org/10.1111/imr.12308>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.; The full-text file will be made open to the public on 18 June 2016 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

1
2
3
4
5
6 **1 Immunological Reviews**
7

8
9 **2**

10
11 **3 Roles of linear ubiquitinylation, a crucial regulator of NF- κ B and cell death, in the immune**
12
13 **4 system**
14
15

16
17 **5**

18
19 **6 Katsuhiro Sasaki and Kazuhiro Iwai**
20

21
22 **7**

23
24 **8 Molecular and Cellular Physiology, Graduate School of Medicine, Kyoto University,**
25
26 **9 Yoshida-konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan**
27
28

29
30 **10**

31
32 **11 Corresponding author: Kazuhiro Iwai**
33

34
35 **12 Molecular and Cellular Physiology, Graduate School of Medicine, Kyoto University,**
36

37
38 **13 Yoshida-konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan**
39

40
41 **14 Tel.: +81-75-753-4671**
42

43
44 **15 Fax: +81-75-753-4676**
45

46
47 **16 E-mail: kiwai@mcp.med.kyoto-u.ac.jp**
48

49
50 **17**

51
52 **18**

53
54 **19**

55
56 **20**
57
58
59
60

21

22 Running title: Linear ubiquitinylation in the immune system

23 Keywords: LUBAC, ubiquitin, linear ubiquitinylation, NF- κ B, inflammation, cell death

24

25 Linear ubiquitinylation, a newly identified post-translational modification, is catalyzed by
26 the linear ubiquitin assembly complex (LUBAC), which is composed of three different
27 subunits, HOIL-1L, HOIP, and SHARPIN. LUBAC plays a critical role in the activation of
28 NF- κ B signaling triggered by a variety of stimuli, including TNF- α , IL-1 β , and
29 pathogen-derived components, and in the protection from cell death. Loss of function of
30 SHARPIN in mice triggers chronic inflammation in multiple organs including the skin, as
31 well as immunodeficiency. In humans, mutations in the gene encoding HOIL-1L cause
32 chronic hyperinflammation and immunodeficiency, which are both associated with
33 decreased levels of LUBAC. The linear ubiquitinylation activity of LUBAC is
34 indispensable for B-cell function in mice, and hyperactivation of LUBAC is associated with
35 oncogenesis in certain forms of B-cell lymphoma. In this short article, the current
36 understanding of the biochemistry of LUBAC-mediated linear ubiquitinylation and its
37 involvement in the immune system are discussed.

38

39 Introduction

40

41 The ubiquitin conjugation system was identified as a part of an energy dependent

42 protein degradation system (1-4). However, non-degradable roles of the ubiquitin system

43 were identified, and ubiquitin conjugation, termed ubiquitinylation, was recognized as a

44 reversible post-translational modification system that controls the functions of key proteins

45 involved in various physiological processes, such as protein degradation, cell cycle,

46 apoptosis, DNA repair, and signal transduction, in all cell types (1, 5-7). Ubiquitin is a

47 highly conserved 76 amino acid globular protein that is encoded by multiple genes, namely,

48 two ubiquitin-ribosomal fusion genes and two polyubiquitin genes (8-11). Ubiquitin is

49 transferred to a lysine residue of a target protein by a cascade of reactions catalyzed by

50 three types of enzymes, a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme

51 (ubiquitin carrier protein) (E2), and a ubiquitin ligase (E3) in an ATP-dependent manner in

52 most cases (12-15) (*Fig. 1*). While conjugation of one ubiquitin to target proteins yields

53 monoubiquitinated proteins, the successive attachment of ubiquitin moieties to

54 ubiquitin-conjugated target proteins results in the generation of polyubiquitinated proteins.

55 E3 ubiquitin ligases determine the specificity of ubiquitinylation by recognizing target

56 proteins, allowing the ubiquitin system to regulate the function of proteins in a timely and

57 specific manner. Ubiquitin can be conjugated to one of seven Lys residues (K6, K11, K27,

58 K29, K33, K48, and K63) or to the amino-terminal Met residue (M1) of ubiquitin

conjugated to target proteins, yielding several types of polyubiquitin chains (16). The type of ubiquitin linkage determines the mode of regulation of the protein (17, 18). The K48 chain targets conjugated proteins for degradation, whereas the K63 chain serves as a specific binding site for the cellular signaling machinery (19, 20). Each type of linkage has distinct structural flexibility: K48-linked di-ubiquitin forms a relatively compact structure, and the K63-linked di-ubiquitin adopts a flexible and open conformation. Different molecular surfaces generated by distinct ubiquitin linkages are specifically recognized by the corresponding ubiquitin binding domains (UBD) (21, 22) (*Fig. 1*). Conjugated ubiquitin molecules are cleaved by deubiquitinating enzymes (DUBs). More than 90 DUBs exist in humans, and some DUBs are specific for particular chain linkages (23, 24) (*Fig. 1*).

This review focuses on a newly identified, M1-linked, linear ubiquitin chain generated by peptide bond formation between the carboxyl group of the C-terminal glycine residue (Gly76) of distal ubiquitin moieties and the α -amino group of the Met1 residue of proximal ubiquitin moieties, and its function in the immune system (25-27). The linear di-ubiquitin has a relatively open conformation of ubiquitin linkages that resembles that of K63-linked di-ubiquitin because the position of M1 is close to that of K63 in ubiquitin (16). Nevertheless, since some UBDs discriminate between the structure of linear and K63 linkages, the linear chain has distinct functions that differ from those of the K63-linked ubiquitin chain. The linear chain is involved in the activation of nuclear factor- κ B (NF- κ B) triggered by various stimuli (28-30). Linear chains also contribute to the regulation of cell

79 death and several pathogenic conditions related to immune cells (31, 32).

80

81 **Enzymology of the linear ubiquitin chain**

82

83 Among multiple ubiquitin genes, the UBB and UBC polyubiquitin genes encode
84 polyubiquitin precursors composed of three and nine ubiquitin moieties. However,
85 translated linear polyubiquitin chains are cleaved into ubiquitin monomers
86 co-translationally by deubiquitinating enzymes (33). Indeed, no linear polyubiquitin can
87 be detected by mass spectrometric analyses, although the presence of ubiquitin linkages via
88 seven Lys residues in ubiquitin was identified in yeast lacking the enzymes that generate
89 linear linkages (34). The linear chain and the enzyme that generates it were first identified
90 in 2006 (27). An E3 ligase complex designated as the linear ubiquitin assembly complex
91 (LUBAC) is the only identified E3 that generates the linear ubiquitin chain. LUBAC is
92 composed of three distinct subunits: HOIL-1L (heme-oxidized IRP2 ligase 1L; also known
93 as RBCK1), HOIP (HOIL-1 interacting protein; also known as RNF31) and SHARPIN
94 (SHANK-associated RH domain-interacting protein) (26, 35, 36) (*Fig. 2*).

95 Both HOIL-1L and HOIP have the RING-IBR-RING (RBR) domain that is a
96 characteristic feature of ubiquitin ligases; however, only the RBR of HOIP, but not that of
97 HOIL-1L, is indispensable for the catalytic activity of linear ubiquitinylation (37). The
98 RBR ubiquitin ligase is part of a newly identified E3 family and thought to be a hybrid type

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of E3 that is homologous to the E6-AP Carboxyl Terminus (HECT) and Really Interesting
New Gene (RING) ligases reported previously (38). The RING E3 ligase, which serves as a
scaffold for ubiquitin-bound E2 and its substrate, allows the ubiquitin to be directly
transferred from the E2 to the substrate. On the other hand, a ubiquitin moiety is usually
transferred to the conserved cysteine residue of the HECT domain before it is transferred to
a substrate in HECT E3 ligases. The RBR E3 ligase has two RING domains and an
amino-terminal classical RING domain (RING1) within the RBR domain that recognize
ubiquitin-bound E2, as observed in RING ligases; the ubiquitin molecule is then transferred
onto the conserved Cys residue of the RING domain (RING2) to form a thioester
intermediate, and ubiquitin bound to the conserved Cys residue is transferred onto a
substrate (*Fig. 3*). Thus, the specificity of ubiquitin linkages is thought to be dependent on
the final state of the thioester intermediate, namely, by the RBR E3. Indeed, LUBAC
specifically generates the linear ubiquitin linkage regardless of the E2s (27) and RING2,
and the linear ubiquitin chain determining domain (LDD) is involved in the linkage
specificity (39).

HOIL-1L and SHARPIN are accessory molecules that are involved in the
stabilization of LUBAC. In cells lacking HOIL-1L or SHARPIN, the other two components
of LUBAC are rapidly degraded via an unknown mechanism, leading to a significant
decrease in the ability for linear ubiquitinylation (25, 26). Interactions between the
ubiquitin-like (UBL) domain of HOIL-1L and ubiquitin-associated (UBA) domain of HOIP

1
2
3
4
5
6
7 119 play a role in the formation of the LUBAC complex, as confirmed by crystallographic
8
9 120 analysis of the complex composed of the UBL domain of HOIL-1L and UBA-containing
10
11 121 HOIP (40). Interactions between HOIP Npl4-type zinc finger/RanBP2 zinc finger (NZF) 2
12
13
14 122 and SHARPIN UBL are also involved in LUBAC formation (41, 42); however, HOIP
15
16
17 123 lacking NZF2, and not UBA, can bind to SHARPIN in cells (26). If the two accessory
18
19 124 molecules are absent, the ligase activity of HOIP is lost almost completely because of the
20
21 125 auto-inhibitory effect of the N-terminal region of HOIP containing UBA domain (41). Thus,
22
23
24 126 HOIL-1L and SHARPIN play crucial roles in enhancing the activity of LUBAC. The
25
26
27 127 molecular weight of LUBAC was estimated at 600 kDa by gel filtration analyses, although
28
29 128 HOIL-1L, HOIP, and SHARPIN are 58 kDa, 120 kDa, and 40 kDa, respectively (26, 27)
30
31
32 129 (*Fig. 2*). Thus, the LUBAC complex is thought to contain at least two or three HOIP
33
34
35 130 components, although the precise subunit composition of the complex remains unknown. It
36
37 131 is awaiting the resolution of the intact crystal structure of the whole ternary complex of
38
39
40 132 LUBAC.

41
42 133 In cells, ubiquitin conjugation to target proteins must be regulated spatially and
43
44
45 134 temporally and induced only when needed. Ubiquitin chains generated in response to
46
47
48 135 various stimuli are recognized by proteins that have specific UBDs to exert their function.
49
50 136 The ubiquitin chains are eventually cleaved by DUBs to abrogate the functions associated
51
52
53 137 with each chain (23, 43). DUBs cleave peptide or isopeptide bonds between ubiquitin and
54
55 138 the substrate, and between ubiquitin molecules (inter-ubiquitin linkage) to dissociate
56
57
58
59
60

ubiquitin from substrates or ubiquitin, leading to the elimination of the activated state. Some linkage-specific DUBs have been reported, and two DUBs, an ovarian tumor (OTU) DUB with linear linkage specificity (OTULIN, also termed Fam105b or Gumby) and cylindromatosis (CYLD), were shown to cleave linear ubiquitin linkages (44-46). The K63 position is very close to the M1 of ubiquitin, and structural analyses revealed that linear and K63 di-ubiquitins are structurally very similar (47, 48). However, OTULIN binds preferentially to linear di-ubiquitin compared to K63 di-ubiquitin (approximately 100-fold higher affinity for the former) and selectively cleaves linear ubiquitin linkages (45). Another DUB, CYLD, can digest linear linkages. CYLD, which was identified as a tumor suppressor commonly mutated in familial cylindromatosis, is involved in the regulation of NF- κ B activation and was shown to cleave K63 chains specifically (49-53). However, CYLD can digest linear linkages in addition to the K63 linkage, as the structure of the K63 chain is similar to that of linear di-ubiquitin (46).

Mice lacking LUBAC subunits or linear chain specific DUBs

Many combinations of E2s and E3s can generate the same ubiquitin linkages. For example, an E2 complex containing Ubc13 generates K63 chains specifically together with multiple E3s. However, in the case of linear chains, LUBAC is the only E3 identified to date that generates linear chains together with multiple E2s. Thus, the function of linear

1
2
3
4
5
6 159 chains could be probed by ablating the activity of LUBAC. However, phenotypes provoked
7
8
9 160 by ablation of subunits of LUBAC, HOIP, HOIL-1L, and SHARPIN are very much
10
11 161 different. First, we describe phenotypes of mice lacking subunits of LUBAC and two DUBs
12
13
14 162 that cleave linear linkages. We then discuss the in vivo roles of these molecules in the
15
16
17 163 immune system.

18
19 164

20
21
22 165 a) HOIP

23
24 166

25
26
27 167 Among the three subunits of LUBAC, HOIP is the catalytic subunit. Therefore,
28
29
30 168 we first describe results obtained with mice having genetically engineered HOIP loci. Mice
31
32 169 lacking the catalytic activity of HOIP were shown to be embryonic lethal, although a
33
34
35 170 precise phenotype was not described yet (54). The HOIP^{-/-} mouse phenotype was reported
36
37 171 recently. HOIP^{-/-} mice die at approximately E10.5 and show disrupted vasculature in the
38
39
40 172 yolk sac (55). This appears to be caused by increased endothelial cell death. Because of its
41
42
43 173 lethality, the function of linear ubiquitin in the immune system could not be addressed
44
45 174 without using conditional knockout (KO) mice. Analyses using conditional KO mice are
46
47 175 discussed later.

48
49
50 176

51
52
53 177 b) SHARPIN

54
55 178
56
57
58
59
60

Mice lacking another subunit of LUBAC, SHARPIN, exhibit different phenotypes. Spontaneous autosomal recessive mutant mice, called chronic dermatitis in mice (*cpdm*), were identified in 1993 as mice exhibiting chronic dermatitis (56). In 2007, SHARPIN was identified as a causative gene product in these mice (26, 35, 36). Two different *cpdm* mouse strains have been described, C57BL/KaLawRij-*Sharpin*^{*cpdm*}/*Sharpin*^{*cpdm*} and CBy.OcB3-*Sharpin*^{*cpdm-Dem*}/*Sharpin*^{*cpdm-Dem*}, both of which have a mutation in the first exon resulting in a frame-shift and the absence of functional SHARPIN proteins (56). Because of the lack of SHARPIN, the amounts of the remaining two components of LUBAC, HOIL-1L and HOIP, are drastically reduced, which markedly decreases linear ubiquitinylation activity although the ligase activity of LUBAC is not completely lost. The characteristic phenotype of both strains of mice is severe chronic inflammation of the skin starting at 5–6 weeks after birth. The skin lesions are identified by epidermal hyperplasia, hyperkeratosis, parakeratosis, scattered apoptotic or necrotic cell death of keratinocytes, and infiltration of granulocytes, macrophages, and mast cells in the dermis and the epidermis (57-60). The development of dermatitis is thought to be independent from acquired immune responses related to lymphocytes because *SHARPIN*^{*cpdm-Dem*} *Rag*^{-/-} double mutant mice, which lack T and B cells, show a similar phenotype to that of *SHARPIN*^{*cpdm-Dem*} mice (61). In addition to the dermatitis, infiltration of neutrophils and macrophages is also seen in multiple organs such as the lung, liver, and several joints. The mice also show structural defects of secondary lymphoid organs,

splenomegaly, a disrupted marginal zone in the spleen, the absence of Peyer's patches in the adult intestine, and reduced levels of serum IgG, IgA, and IgE, but not IgM, which indicates defective class switching in B cells (62, 63).

When *cpdm* mice are crossed with $\text{TNF}\alpha^{-/-}$ mice, the dermatitis, but not the systemic inflammatory effects on other organs, of *cpdm* mice are drastically rescued, even though they carry a heteroallelic deletion of $\text{TNF-}\alpha$ (36). Moreover, intercrossing *cpdm* mice with RIP1 kinase dead mice cures the *cpdm* symptoms almost completely (64). The upregulation of HOIP and HOIL-1L in the skin also ameliorates *cpdm* mice and attenuates NF- κ B activation. Thus, a reduction of LUBAC, and thereby of linear ubiquitylation activity, associated with the loss of function of SHARPIN and its effects on inhibiting NF- κ B and promoting cell death underlie the pathogenesis of *cpdm* mice.

c) HOIL-1L

Loss of HOIL-1L in mice has also been reported (25). Loss of HOIL-1L destabilizes the other two components of LUBAC and reduces the linear ubiquitylation activity of LUBAC. Signal-induced NF- κ B activation is attenuated; however, HOIL-1L KO mice do not exhibit overt phenotypes. This can be attributed to the fact that lack of HOIL-1L enhances cell death only marginally.

219 d) OTULIN

220

221 Homozygous mutant mice carrying a mutation in OTULIN (W96R) called *gumby*
222 mice, which exhibit virtually no DUB activity (65), die at E10.5 and show defects in the
223 organization of branching vascular networks in the head and trunk. Linear ubiquitinated
224 proteins accumulate in *gumby* embryos compared to control embryos (65). The Wnt
225 signaling pathway, which is essential for the sprouting of blood vessels from the
226 pre-existing vasculature during angiogenesis, is activated in *gumby* mice because of
227 impaired linear DUB activity. Indeed, OTULIN interacts with disheveled 2 (DVL2), a
228 critical protein involved in the canonical Wnt pathway, and suppresses canonical Wnt
229 signaling in overexpression studies (46).

230

231 f) CYLD

232

233 Since CYLD can cleave K63 in addition to linear linkages, its functions are not
234 defined by the cleavage of linear chains alone. Familial cylindromatosis, of which CYLD is
235 a causative gene product, is characterized by multiple benign tumors that develop from skin
236 appendages, such as hair follicles and sweat glands (49, 66, 67). In animal models, *CYLD*^{-/-}
237 mice do not develop spontaneous tumors; however, they are highly susceptible to dextran
238 sulfate sodium (DSS)-induced colitis and azoxymethane (AOM)-induced tumor

development (68, 69). Thus, CYLD plays a critical role in the suppression of tumor proliferation (53). Overexpression of CYLD leads to a decrease in NF- κ B activity induced by several receptors including TNFR1, CD40, TLR4, EDAR, and LMP1 (51, 70). Moreover, CYLD interacts with TNFR1-associated factor (TRAF)2 and TRAF6 and impairs their linear ubiquitinylation via its deubiquitinating activity (51). In addition, CYLD was suggested to be involved in the induction of cell death (71-75).

245

246 **Mechanistic insight into the functions of linear ubiquitinylation**

247

Next we discuss the function of linear ubiquitin chains. Accumulating evidence supports the involvement of linear ubiquitin chains in canonical NF- κ B activation and the regulation of cell death. Here, we summarize current knowledge on the molecular mechanisms underlying canonical NF- κ B activation and cell death regulation mediated by linear ubiquitinylation. Other functions of linear ubiquitin chains are also discussed.

253

254 **a) NF- κ B activation**

255

The first identified function of the linear ubiquitin chain was its involvement in the activation of the canonical NF- κ B pathway. NF- κ B is a member of a family of dimeric transcription factors composed of five Rel homology domain (RHD)-containing proteins,

including RelA (p65), RelB, c-Rel, p105/p50 (NF- κ B1), and p100/p52 (NF- κ B2). The RHD in the amino-terminal region is required for dimerization, nuclear import, and binding to 9–10 base pair NF- κ B-responsive elements referred to as κ B sites. NF- κ B is involved in various biological processes including immune responses, inflammation, and cell survival. Aberrant activation of NF- κ B plays a role in immunological disorders and oncogenesis, including some forms of B-cell lymphoma (76, 77). Two NF- κ B activation pathways have been described, the canonical (classical) and alternative (non-canonical) pathways, which have distinct physiological consequences (78-80). Here, the canonical pathway is introduced because LUBAC-mediated linear ubiquitinylation is involved in the canonical but not the alternative pathway (25, 26, 54) (*Fig. 4*). Various ligands induce the activation of the canonical NF- κ B pathway, which is associated with local inflammatory and immune responses. In the resting state, NF- κ B is restrained in the cytoplasm through binding to inhibitor of NF- κ B (I κ B) proteins. I κ Bs, which include I κ B α , I κ B β , and I κ B ϵ , associate with the RHDs of NF- κ B via their ankyrin-repeat motif. The I κ B kinase (IKK) complex is composed of IKK1 (IKK α), IKK2 (IKK β), and NF- κ B essential modulator (NEMO; also called IKK γ), and is a critical mediator of the canonical NF- κ B pathway (78, 79, 81). Upon activation by various stimuli, the IKK complex is activated by phosphorylation of specific serine residues on IKK2 and induces the phosphorylation of I κ Bs. Phosphorylated I κ Bs are recognized by the SCF ^{β TrCP} ubiquitin ligase, followed by K48-linked ubiquitinylation and degradation via the proteasome (82-85) (*Fig. 4*). LUBAC plays a role in the canonical

279 NF- κ B pathway triggered by TNF- α , IL-1 β , CD40 ligand (CD40L), and certain Toll-like
280 receptors (TLRs) (25, 35, 54). The current hypothesis for the role of LUBAC-mediated
281 linear ubiquitinylation in canonical NF- κ B activation triggered by ligands of the TNFR
282 family is as follows: upon activation by various stimuli, LUBAC preferentially recognizes
283 and conjugates linear ubiquitin chains on NEMO (25, 86). Mutational analysis revealed that
284 the interaction between the NZF1 domain of HOIP and the coiled-coil 2 and leucine zipper
285 (CoZi) domains of NEMO is involved in LUBAC-mediated linear ubiquitinylation at
286 Lys285 and Lys309 in the CoZi domain of NEMO (25). NEMO possesses a specific
287 ubiquitin binding region referred to as the ubiquitin binding in ABIN and NEMO (UBAN)
288 motif within the CoZi domain (87). The UBAN motif has high affinity for linear
289 di-ubiquitin, but not for K63 di-ubiquitin chains (87, 88). Recognition of the linear
290 di-ubiquitin conjugated to NEMO by the UBAN domain of another NEMO in *trans* may
291 trigger dimerization of the IKK complex, and subsequent trans-autophosphorylation of two
292 specific Ser residues of IKK2, because amino acid residues in the kinase domain of IKK2
293 involved in IKK2 dimerization are required for IKK2 phosphorylation (89) (*Fig. 4*). Upon
294 activation by various stimuli, recognition of NEMO conjugated linear ubiquitin chains by
295 the UBAN domain of NEMO, which is specific for the linear chain, triggers NF- κ B
296 activation. Thus, DUBs that cleave linear chains are thought to block the signal generated
297 by conjugation of linear ubiquitin chains. Recently, two DUBs, OTULIN and CYLD, which
298 can cleave linear chains, were shown to bind continuously to LUBAC via the peptide

299 N-glycosidase (PNGase)/ubiquitin-associated (PUB) domain of HOIP (46, 90, 91). The
300 ligase-DUB interaction is not regulated by any stimulus (46). The activation of NF- κ B by
301 TNF- α is intensified in HOIP null cells expressing a HOIP mutant that is unable to interact
302 with OTULIN or CYLD compared to that in cells expressing wild-type HOIP. Thus, the
303 ligase-DUB interaction may play a role in the optimization of the strength of the signal
304 initiated by stimuli, possibly by modulating the length or number of linear ubiquitin chains.
305 Phosphorylation of a Tyr residue in the PUB-interacting motif of OTULIN abolishes the
306 interaction between the two proteins (90, 91); therefore, signaling mediated by linear chains
307 might be modulated by the activation of tyrosine kinases. The precise role of the interaction
308 between LUBAC and the two DUBs remains to be elucidated.

309 Another DUB, A20, is involved in the suppression of linear chain-mediated
310 NF- κ B activation, although it functions in a DUB-independent manner (92, 93). A20,
311 identified as a suppressive factor for NF- κ B signaling upon TNFR and TLR stimulation (94,
312 95), contains seven Cys₂-Cys₂ zinc finger (ZF) repeats in the carboxyl-terminal region in
313 addition to the N-terminal OTU domain. A20 attenuates NF- κ B activation by cleaving K63
314 chains on RIP1 and conjugating K48 chains onto RIP1, leading to the degradation of the
315 kinase (95). A20 was also shown to suppress LUBAC-mediated NF- κ B activation via the
316 linear chain specific binding activity of the seventh zinc finger (ZF7), possibly by
317 preventing the recruitment of LUBAC and NEMO to the activated receptor complex (92,
318 96). Considering that A20 is a target of NF- κ B and rapidly induced after stimulation, it may

319 be a key factor in a negative feedback loop modulating NF- κ B-induced gene expression.

320 Linear ubiquitinylation is also involved in NF- κ B activation via the
321 nucleotide-binding oligomerization domain-containing (NOD)-like receptors (NLRs) NOD
322 1 and 2, which are cytoplasmic pattern recognition receptors (PRRs) (97, 98). NOD1 and
323 NOD2 selectively recognize bacterial PGN found in both gram-positive and gram-negative
324 bacteria. NOD receptor signaling is initiated by the interaction between NODs and RIP2,
325 which is mediated by the homotypic interaction between their caspase recruitment domains
326 (CARDs). The baculovirus IAP repeat 2 (BIR2) domain of RIP2 then recruits X-linked IAP
327 (XIAP), an E3 ligase with a RING domain, which ubiquitinates RIP2 leading to NF- κ B
328 activation (97). Although RIP2 is modified by K63 polyubiquitinylation in NODs signaling,
329 the ligase activity of LUBAC is also involved in NOD2-mediated NF- κ B activation. The
330 dependence of the interaction between LUBAC and the NOD signaling complex on the
331 ubiquitin ligase activity of XIAP suggests that LUBAC is recruited to the NOD signaling
332 complex via recognition of XIAP-generated ubiquitin chains. The major linear
333 ubiquitinated protein involved in NOD signaling is RIP2. NOD2 signaling is also limited
334 by OTULIN via cleavage of RIP2-conjugating linear ubiquitin chains. Accordingly,
335 deletion of OTULIN increases the linear ubiquitinylation of RIP2 in response to NOD2
336 stimulation. However, the role of the linear ubiquitinylation of RIP2 in NOD2 signaling
337 remains unknown. NEMO might also be ubiquitinated in this setting and involved in
338 NF- κ B activation, despite the fact that NEMO ubiquitinylation has not been convincingly

339 detected (99).

340 Linear ubiquitinylation is also involved in canonical NF- κ B activation mediated
341 by membrane PRRs, TLRs. TLR ligand-induced canonical NF- κ B activation is mediated by
342 Myd88 (100, 101). Upon stimulation with TLR ligands, Myd88 is recruited to activated
343 TLRs, followed by recruitment of the TRAF6 ubiquitin ligase. K63 chains generated by
344 TRAF6 on TRAF6 itself or on other proteins in the activated receptor complex may
345 function as a recruitment signal for LUBAC and induce NF- κ B activation. Linear
346 ubiquitinylation is also involved in IL-1 β -mediated NF- κ B activation, in which Myd88 also
347 plays a role, since linear ubiquitinylation of NEMO was detected in cells stimulated with
348 IL-1 β (25). However, residual NF- κ B activation in cells lacking linear ubiquitinylation
349 activity differs among stimuli and cells: IL-1 β -mediated NF- κ B activation in mouse
350 embryonic fibroblasts (MEFs) is more severely suppressed than that mediated by TLR9
351 ligands in B cells lacking LUBAC's ligase activity (54). Moreover, LUBAC-mediated
352 linear ubiquitinylation is dispensable for NF- κ B activation induced by B-cell antigen
353 receptor, although CD40-mediated NF- κ B activation is impaired almost completely in B
354 cells lacking the catalytic center of HOIP (54). In addition, a ligase-independent role of
355 LUBAC in NF- κ B activation was suggested (102). Thus, current results indicate the
356 existence of several pathways for the activation of IKK.

357 The involvement of another polyubiquitin chain, the K63-ubiquitin chain, in
358 NF- κ B activation was also suggested (29, 103, 104). In this scenario, K63 chains function

as platforms to recruit both IKK and the TAK1 complex, which is composed of TAK1, TAB1, and TAB2 and/or TAB3, via the ubiquitin binding activities of NEMO and TAB2 and/or TAB3, respectively. Then, the TAK1 kinase phosphorylates IKK2, leading to IKK activation. However, since binding of NEMO to K63 is weak because the UBAN domain of NEMO prefers linear di-ubiquitin to K63 di-ubiquitin (87), K63 chains alone may not be enough to activate IKK. Recently, mixed ubiquitin chains, in which both linear and K63 linkages co-exist, were identified (105). The TAK1/TAB2/TAB3 and the IKK complex can be recruited to the mixed chain via K63 and linear ubiquitin binding activities, respectively (106). This leads to the phosphorylation of the Ser residues of IKK2 by TAK1 and by trans-autophosphorylation induced by linear chains (89). Linear ubiquitin chains appear to play central roles in canonical NF- κ B activation induced by ligands of the TNF receptor family; however, further analyses are necessary to clarify the roles of linear ubiquitin chains in IKK activation completely. abolishes

b) ERK activation.

In addition to their involvement in NF- κ B activation, linear chains play a role in ERK activation (54). In B cells and macrophages, IKK activates ERK via TPL2 phosphorylation (107, 108). Loss of the linear ubiquitinylation activity of LUBAC abolishes CD40- and TLR-mediated ERK activation in B cells almost completely (54).

Thus, linear ubiquitinylation plays a role in ERK activation through IKK, which is activated by linearly polyubiquitinated NEMO (54). However, B-cell receptor (BCR)-mediated ERK activation is not overtly affected in B cells lacking the catalytic center of HOIP, indicating that multiple ERK activation pathways exist in B cells (54).

c) Cell death regulation

Certain TNFR family receptors such as TNF receptor 1 (TNFR1) trigger cell death signals, and LUBAC-mediated linear ubiquitinylation is involved in the regulation of TNFR1-mediated cell death; however, the linearly ubiquitinated substrates involved in cell death regulation remain to be identified (36, 109, 110). TNFR1 is constitutively expressed on the surface of almost all cell types and plays a role in immune and inflammatory responses during infection, cell proliferation, and the regulation of the programmed cell death processes known as apoptosis and necroptosis (programmed necrosis). TNF- α and lymphotoxin alpha (LT- α , also referred to as TNF- β) are the ligands of the receptor. Activation of TNFR1 is initiated by its trimerization on the cellular membrane in response to the binding of extracellular ligands. This leads to a conformational change in the intracellular death domain (DD) of TNFR1 that results in the recruitment of two DD-containing adaptor proteins, TNFR-associated death domain (TRADD) and receptor interacting protein 1 (RIP1), through direct interaction between the

DDs (*Fig. 4*). Certain ubiquitin E3 ligases such as TRAF2, and cellular inhibitor of apoptosis protein 1 and 2 (cIAP1, 2) are recruited to activated TNFR1 via TRADD to assemble a signaling complex known as complex I at the cell membrane (111, 112). In addition to the known components of complex I, LUBAC is also recruited to the activated TNFR1 complex (113). The recruitment of LUBAC to the TNFR1 signaling complex is dependent on the ubiquitin ligase activity of cIAP1 and cIAP2. The NZF domains are UBDs, and the HOIP NZF1 domain can recognize ubiquitin and NEMO simultaneously (89). The ubiquitin binding activity of the NZF1 domain of HOIP is critical for the recruitment of LUBAC to the activated TNF receptor complex and possibly functions by recognizing ubiquitin chains conjugated by cIAPs (*Fig. 5*) (113). cIAPs ubiquitinyrate not only the components of the TNFR1 signaling complex including RIP1, but also undergo auto-ubiquitinylation, eventually leading to the generation of high amounts of various types of ubiquitin chains, including K63 chains. Recognition of K63 chains by HOIP NZF1 may be involved in the recruitment of LUBAC to the activated TNFR1 complex (113). K11-linked chains generated by cIAPs are involved in canonical NF- κ B activation, suggesting that the HOIP NZF binds to K11 chains, although this has not been definitely proven (114). The recruitment of LUBAC to the activated TNFR1 complex may lead to the recruitment of IKK and the linear ubiquitinylation of NEMO, resulting in the activation of NF- κ B.

The linear ubiquitinylation activity of LUBAC is required for the protection of

cells from TNF- α -mediated cell death. LUBAC can induce the expression of anti-apoptotic genes including Bcl2 and cFLIP by activating NF- κ B. In addition, LUBAC inhibits TNF- α -mediated cell death by a different mechanism. The transition from complex I to complex II triggers cell death. TNFR1 induces two types of programmed cell death, apoptosis and necroptosis, both of which can be initiated by the formation of complex II, which is composed of TRADD, FADD, caspase 8, RIP1, and possibly RIP3 (*Fig. 5*). Caspase 8 is activated by dimerization and digests RIP1 and RIP3, leading to apoptosis. When caspase 8 is inactivated, RIP1 and RIP3 kinases are activated by trans- or auto-phosphorylation, which triggers necroptosis (115-117). The linear ubiquitinylation activity of LUBAC plays a role in suppressing the formation of complex II, although the linear ubiquitinylation substrates involved in the inhibition of complex II formation have not been convincingly identified yet (36). The removal of K63 linked chains by the A20 or CYLD DUBs from RIP1 is involved in complex II formation (95, 118-121). However, RIP1 is modified by multiple types of chains, including K11 and linear chains in addition to K63 chains. Considering that the linear ubiquitinylation activity of LUBAC is required for the inhibition of complex II formation, the linear ubiquitinylation of RIP1 might be involved in the inhibition of TNF- α mediated cell death by LUBAC. However, further analyses are needed to clarify the role of LUBAC-mediated linear ubiquitinylation in cell death regulation.

438

439 d) Other functions

440

441 The involvement of LUBAC-mediated linear ubiquitinylation in other functions
442 was investigated using HOIL-1L^{-/-} or *cpdm* mice.

443

444 d)-1 Regulation of inflammasome formation

445

446 Pyrin domain-containing 3 (NLRP3), an NLR, functions in the assembly of the
447 inflammasome, which promotes the production of proinflammatory cytokines, mainly
448 IL-1 β and IL-18 (122, 123). NLRP3 senses several pathogen-associated molecular patterns
449 (PAMPs) as well as host damage-associated molecular patterns (DAMPs) released from
450 injured and necrotic cells. The activated NLRP3 and the adaptor protein ASC act together
451 to assemble the inflammasome, which potentiates the cleavage of pro-caspase 1, followed
452 by the release of two active forms, the p10 and p20 domain-containing subunits. The
453 resultant active caspase 1 cleaves pro-IL-1 β and pro-IL-18 to generate the mature
454 proinflammatory cytokines. Thus, NLRP3 is involved in innate immune responses through
455 the rapid production of IL-1 β and IL-18. Formation of the NLRP3-ASC inflammasome is
456 attenuated in bone marrow derived macrophages (BMDMs) from HOIL-1L^{-/-} mice. ASC
457 was identified as a substrate for linear ubiquitinylation associated with inflammasome
458 formation, although the roles of linearly ubiquitinated ASC in inflammasome formation

have not been addressed. Reduction of LUBAC levels affects the activation of the inflammasome, and the secretion of IL-1 β in BMDMs of HOIL-1L^{-/-} mice is suppressed independently of NF- κ B signaling (124). Of note, the RBR domain of HOIL-1L is required for the linear ubiquitinylation of ASC in addition to HOIP RBR, although the RBR domain of HOIL-1L is dispensable for the generation of linear ubiquitin chains (124). The proposed involvement of the RBR domain of HOIL-1L in NEMO ubiquitinylation (86) indicates that the HOIL-1L RBR may be required for ASC linear ubiquitinylation.

d)-2 Inhibition of RIG-I signaling

Retinoic acid-inducible gene-I (RIG-I) belongs to the RIG-I-like receptor (RLR) family among the PRRs, and serves as a cytoplasmic virus RNA sensor that facilitates innate antiviral responses through the upregulation of type I IFNs, IFN- α and IFN- β (122, 125). Upon recognition of viral RNA, RIG-I is conjugated with K63-linked ubiquitin chains generated by TRIM25, which facilitates interaction with an adaptor protein, mitochondrial antiviral signaling protein (MAVS) through their CARD domains. Subsequently, RIG-I interacts with TRAF3 via the TRAF-interacting motifs (TIM) of MAVS, leading to the recruitment of NF- κ B signaling related-proteins including NEMO and IKK-dependent NF- κ B activation (126). Unlike other PRR-mediated signaling mechanisms, LUBAC-mediated linear ubiquitinylation negatively regulates

1
2
3
4
5
6 479 RIG-I-mediated signaling (127). NEMO conjugated with linear ubiquitin chains, but not
7
8
9 480 unmodified NEMO, interacts with TRAF3, which interferes with the assembly of the
10
11 481 MAVS-TRAF3 complex and eventually inhibits anti-virus IFN secretion (127). Consistent
12
13
14 482 with this concept, the MEFs of SHARPIN-deficient *cpdm* mice show increased IFN
15
16
17 483 mediated antiviral responses when infected with vesicular stomatitis virus (VSV), which is
18
19 484 a negative-strand RNA virus (128). Another report suggested that HOIL-1L and HOIP
20
21
22 485 suppress RIG-I signaling induced by Sendai viruses through the inhibition of
23
24 486 RIG-I-TRIM25 interaction, which is mainly mediated by TRIM25 degradation in
25
26
27 487 HOIL-1L^{-/-} MEFs with suppressed HOIP expression. In this scenario, TRIM25 is identified
28
29
30 488 as a LUBAC substrate (129). The linear ubiquitin chain may function as a degradation
31
32 489 signal, albeit weak (27, 130); however, further investigation is necessary to identify the role
33
34
35 490 of LUBAC in RIG-I signaling.

36
37 491
38
39
40 492 **Analysis of the pathophysiological roles of linear ubiquitylation using LUBAC**
41
42 493 **mutant mice**

43
44 494
45
46
47 495 The phenotypes of mice lacking components of LUBAC are drastically diverse
48
49
50 496 because of differences in the residual amount of functional LUBAC mainly. No LUBAC
51
52
53 497 complex or linear ubiquitylation activity is observed in HOIP^{-/-} mice. No linear
54
55
56 498 ubiquitylation activity can be detected in mice expressing C-terminal deleted HOIP or a
57
58
59
60

ubiquitin binding deficient HOIP mutant in HOIP null mice despite the presence of the LUBAC complex. Mice lacking HOIL-1L (HOIL-1L^{-/-}) or SHARPIN (*cpdm*) express a LUBAC complex composed of the other two subunits, although the amount of residual LUBAC is drastically reduced because of the destabilization of LUBAC provoked by the loss of one subunit. The linear ubiquitylation activity is reduced but present in mice lacking SHARPIN or HOIL-1L. In addition, SHARPIN or HOIL-1L that does not form a complex with HOIP exists in cells. Indeed, LUBAC independent functions of SHARPIN or HOIL-1L were reported. SHARPIN controls lymphocyte migration via direct interaction with β 1-integrin or lymphocyte-function-associated antigen-1 (LFA-1) (131, 132). HOIL-1L targets protein kinase C ζ for degradation under hypoxic conditions to promote tumor survival (133). Therefore, results obtained using HOIL-1L^{-/-} or *cpdm* mice, which are not linear chain null mice, need to be interpreted with caution.

a) Mechanism underlying *cpdm* pathology

SHARPIN-deficient *cpdm* mice and HOIL-1L^{-/-} mice are both defective in NF- κ B activation because of instability of the LUBAC complex. Suppressed NF- κ B activation is characterized by delayed phosphorylation of I κ B α and decreased expression of NF- κ B-targeting genes in response to TNF- α stimulation in both types of mutant mice (25, 26). Nevertheless, *cpdm* mice, but not HOIL-1L^{-/-} mice, develop chronic dermatitis as

described above (29). TNF- α signaling plays a role in the pathogenesis of *cpdm*, as intercrossing *cpdm* mice with TNF- α null mice ameliorates chronic dermatitis (35). The main functions of LUBAC-mediated linear ubiquitinylation are its contribution to canonical NF- κ B activation and cell death regulation. NF- κ B activation is suppressed in both *cpdm* and HOIL-1L^{-/-} mice at comparable levels (25, 26). MEFs from *cpdm* mice are more sensitive to TNF- α -induced cell death than those from HOIL-1L^{-/-} mice despite the fact that TNF- α -induced cell death is strongly induced in HOIL-1L^{-/-} cells (25). TNF- α induces two types of programmed cell death, apoptosis and necroptosis, and the latter is more prone to induce inflammation than the former (134, 135). To investigate the role of necroptosis and apoptosis in *cpdm* pathology, *cpdm* mice are crossed with mice lacking molecules involved in these two types of programmed cell death. Deletion of RIP3 or mixed lineage kinase domain-like protein (MLKL), which are both involved in necroptosis, only partially ameliorates *cpdm* symptoms (109, 110). Caspase 8 or FADD is involved in the induction of apoptosis. However, their deletion promotes necroptosis. Deficiency of caspase 8 or FADD specifically in keratinocytes combined with RIP3 ameliorated *cpdm* symptoms almost completely (109, 110). Moreover, crossing *cpdm* mice with mice expressing kinase-negative RIP1, which impairs necroptosis and certain forms of apoptosis, cured *cpdm* dermatitis completely (64). Thus, both apoptosis and necroptosis are involved in *cpdm* pathology.

A recent report showed that the *Rnf31* gene, which encodes HOIP, is located

between the *Psme2* and *Irf9* genes, both of which are induced by interferon- γ (IFN- γ). In addition, the *Rnf31* gene was shown to have an IFN regulatory factor 1 and two IFN- γ -responsive regulatory elements on the upstream and downstream regions of the genes, respectively (136). As expected, mRNA transcription of HOIP was increased after IFN- γ treatment. Increased protein levels of both HOIL-1L and SHARPIN in addition to HOIP were observed in MEFs, BMDMs, and primary keratinocytes in response to type I and type II IFN, which are induced mainly by immune cells including activated lymphocytes after RNA or DNA virus infection leading to enhanced activation of NF- κ B (136). Moreover, intradermal injection of type I or type II IFN ameliorated *cpdm* dermatitis by upregulating HOIP expression in the skin, indicating that reduction of residual LUBAC underlies *cpdm* pathology. Therefore, attenuated NF- κ B activation may also underlie *cpdm* pathology although NF- κ B is known as a proinflammatory transcription factor (137). It is, thus, of interest to determine the phenotype of mice with further reduction of LUBAC composed of SHARPIN and HOIP in HOIL-1L^{-/-} mice.

b) Investigating the role of LUBAC-mediated linear ubiquitinylation in B lymphocytes

To dissect the functions of linear ubiquitin chains, it is indispensable to use mice lacking HOIP or the linear ubiquitinylation activity of HOIP. However, complete loss of the linear ubiquitinylation activity of LUBAC is associated with embryonic lethality. Therefore,

the roles of linear ubiquitin chains in the immune system should be probed using tissue or cell type specific deletion of LUBAC ligase activity. Mice lacking the C-terminal part of HOIP, which contains the catalytic center for linear ubiquitinylation (B-HOIP Δ linear mice), were used to investigate the roles of LUBAC-mediated linear ubiquitinylation in B lymphocytes (54). The development of conventional B cells, both follicular and marginal B cells, was not affected by the loss of linear ubiquitinylation activity of LUBAC. However, the effector functions of B cells were heavily affected, with almost complete suppression of responses to thymus-dependent antigen and thymus-independent antigen II. Moreover, differentiation of B1 cells, which reside in the peritoneum, was heavily impaired by the loss of LUBAC ligase activity, and the serum titers of all subclasses of antibodies in resting stages were suppressed. These results indicated that the linear polyubiquitinylation activity of LUBAC plays crucial roles in B cells. Biochemical analyses revealed that canonical NF- κ B and ERK activation mediated by the TNFR family receptors CD40 and transmembrane activator and CAML interactor (TACI) is attenuated in B cells from B-HOIP Δ linear mice. CD40-induced JNK or alternative NF- κ B activation is not overtly affected in HOIP Δ linear B cells. Activation of canonical NF- κ B and ERK by TLR4 and TLR9 is also attenuated albeit less significant than that mediated by CD40. In this study, BCR-mediated signaling, which plays an important role in B1 cell development (138), was not affected by the loss of linear ubiquitinylation activity. These results suggest that receptors other than BCR play a role in B1-cell development through the activation of the canonical NF- κ B

pathway. However, the involvement of LUBAC in BCR-mediated canonical NF- κ B activation via a ligase-independent mechanism was suggested in another study (139).

Loss of HOIL-1L in patients and mice

Patients with bi-allelic mutations in HOIL-1L genes have been reported (31, 140, 141). Fibroblast cells from these patients decreased protein levels of the other LUBAC components, HOIP and SHARPIN, and impaired TNF- α and IL-1 β induced NF- κ B activation. In one study, chronic hyperinflammation, invasive bacterial infections associated with mild immunodeficiency, cardiomyopathy, and muscular amylopectinosis were detected in three patients, whereas the remaining 13 showed cardiomyopathy and muscular amylopectinosis, but no immunological symptoms (31).

HOIL-1L^{-/-} mice do not show any overt phenotypes under pathogen-free conditions, although deposition of amylopectin-like materials could be observed in the aging heart (142). On the other hand, HOIL-1L^{-/-} mice are susceptible to acute infections by several pathogens including *Listeria monocytogenes*, indicating that HOIL-1L^{-/-} mice are immunodeficient (142). HOIL-1L^{-/-} mice are resistant to chronic infection by murine γ -herpesvirus 68 (MHV68), suggesting that chronic herpesvirus infection generates signs of auto-inflammation. These results imply that the lack of immunological symptoms in HOIL-1L^{-/-} mice is due to the pathogen-free conditions.

599

600 **LUBAC in diseases**

601

602 In addition to the role of mutations in HOIL-1L genes, the involvement of
603 LUBAC-mediated linear ubiquitinylation in disease was revealed recently. Aberrant NF- κ B
604 activation plays a critical role in the oncogenesis of activated B-cell-like diffuse large
605 B-cell lymphomas (ABC DLBCL) (139). Yang et al. reported that SHARPIN and HOIP are
606 essential for the growth of ABC DLBCL cells but not germinal center B-cell-like (GCB)
607 DLBCL cells through the suppression of NF- κ B activation. They also showed that two rare
608 SNPs of the HOIP gene are highly enriched in ABC DLBCL (139). Mutations of the A20
609 DUB that abrogate linear ubiquitin binding activity of the protein were reported in Hodgkin
610 and non-Hodgkin B-cell lymphomas (92). Attenuated LUBAC expression suppresses lung
611 metastases of osteosarcomas in mice (143). Moreover, downregulation of HOIP or
612 SHARPIN expression promoted apoptosis induced by platinum-based genotoxins,
613 including cisplatin and carboplatin, which are widely used anti-cancer drugs (144). Thus,
614 LUBAC activity might be a suitable target to control malignant tumors. Gliotoxin, a major
615 virulence factor of the opportunistic pathogen *Aspergillus fumigatus*, was recently
616 identified as a specific inhibitor of LUBAC-mediated linear ubiquitinylation (145), which
617 highlights the crucial roles of linear ubiquitinylation in the protection from infectious agents
618 and the possibility of isolating LUBAC inhibitors from natural products.

Concluding remarks

The present short article introduces the roles of the recently identified ubiquitin modification, linear ubiquitinylation, in the immune system. Linear polyubiquitin chains and LUBAC were identified in 2006 during analyses aimed at elucidating the molecular mechanism underlying the generation of polyubiquitin chains (27). To date, linear ubiquitinylation has been shown to play a role in inflammation, immune responses, and oncogenesis, as expected from its involvement in NF- κ B activation. Inhibitors of LUBAC-mediated linear ubiquitinylation were suggested as suitable candidates for the treatment of malignant tumors. In addition, the finding that the ubiquitin ligase activity of LUBAC is induced by type I and type II IFNs implies a novel connection between the IFN and NF- κ B pathways. The fact that phosphorylation of a Tyr residue in OTULIN, a linear chain specific DUB, suppresses the interaction between OTULIN and LUBAC, indicates crosstalk between Tyr phosphorylation and NF- κ B activation. Thus, the roles of linear ubiquitinylation might not be limited to NF- κ B activation or cell death regulation. In addition to NEMO and A20, proteins containing linear chain specific UBDs were reported. For example, the UBAN motif of Optineurin, which is a product of a mutated gene in glaucoma and amyotrophic lateral sclerosis, can recognize linear di-ubiquitin (146-148). Moreover, Optineurin is an autophagy receptor involved in the autophagic clearance of

639 cytosolic Salmonella (146). The study of linear ubiquitin chains is just beginning. Further
640 analyses may reveal additional unexpected roles of linear ubiquitin chains in the near
641 future.

642

643 Acknowledgment

644

645 The authors have no conflicts of interest.

646

647 References

648

- 649 1. Hershko A, Ciechanover A. The ubiquitin system. *Annu Rev Biochem*
650 1998;67:425-479.
- 651 2. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the
652 polyubiquitin proteolytic signal. *EMBO J* 2000;19:94-102.
- 653 3. Verma R, McDonald H, Yates JR, 3rd, Deshaies RJ. Selective degradation of
654 ubiquitinated Sic1 by purified 26S proteasome yields active S phase cyclin-Cdk. *Mol Cell*
655 2001;8:439-448.
- 656 4. Finley D. Recognition and processing of ubiquitin-protein conjugates by the
657 proteasome. *Annu Rev Biochem* 2009;78:477-513.
- 658 5. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in
659 endocytosis and signaling. *Science* 2007;315:201-205.
- 660 6. Wickliffe K, Williamson A, Jin L, Rape M. The multiple layers of
661 ubiquitin-dependent cell cycle control. *Chem Rev* 2009;109:1537-1548.
- 662 7. Zinngrebe J, Montinaro A, Peltzer N, Walczak H. Ubiquitin in the immune
663 system. *EMBO Rep* 2014;15:28-45.

- 664 8. Ozkaynak E, Finley D, Varshavsky A. The yeast ubiquitin gene: head-to-tail
665 repeats encoding a polyubiquitin precursor protein. *Nature* 1984;312:663-666.
- 666 9. Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin
667 homeostasis. *J Biochem* 2010;147:793-798.
- 668 10. Finley D, Ozkaynak E, Varshavsky A. The yeast polyubiquitin gene is essential
669 for resistance to high temperatures, starvation, and other stresses. *Cell* 1987;48:1035-1046.
- 670 11. Catic A, Ploegh HL. Ubiquitin--conserved protein or selfish gene? *Trends*
671 *Biochem Sci* 2005;30:600-604.
- 672 12. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. *Annu Rev*
673 *Biochem* 2009;78:399-434.
- 674 13. Scheffner M, Nuber U, Huibregtse JM. Protein ubiquitination involving an
675 E1-E2-E3 enzyme ubiquitin thioester cascade. *Nature*. 1995;373:81-83.
- 676 14. Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. *Nat Rev Mol Cell*
677 *Biol* 2009;10:755-764.
- 678 15. Lee I, Schindelin H. Structural insights into E1-catalyzed ubiquitin activation and
679 transfer to conjugating enzymes. *Cell*. 2008;134:268-278.
- 680 16. Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of
681 polyubiquitin beyond Lys48 and Lys63 linkages. *Nat Rev Mol Cell Biol* 2012;13:508-523.
- 682 17. Fu QS, Song AX, Hu HY. Structural aspects of ubiquitin binding specificities.
683 *Curr Protein Pept Sci*. 2012;13:482-489.
- 684 18. Hurley JH, Lee S, Prag G. Ubiquitin-binding domains. *Biochem J*
685 2006;399:361-372.
- 686 19. Komander D, Rape M. The ubiquitin code. *Annu Rev Biochem* 2012;81:203-229.
- 687 20. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. *Mol*
688 *Cell* 2009;33:275-286.
- 689 21. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to
690 functions. *Nat Rev Mol Cell Biol* 2009;10:659-671.
- 691 22. Hicke L, Schubert HL, Hill CP. Ubiquitin-binding domains. *Nat Rev Mol Cell*
692 *Biol* 2005;6:610-621.
- 693 23. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of

- the deubiquitinases. *Nat Rev Mol Cell Biol* 2009;10:550-563.
24. McGouran JF, Gaertner SR, Altun M, Kramer HB, Kessler BM. Deubiquitinating enzyme specificity for ubiquitin chain topology profiled by di-ubiquitin activity probes. *Chem Biol* 2013;20:1447-1455.
25. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K, et al. Involvement of linear polyubiquitylation of NEMO in NF- κ B activation. *Nat Cell Biol* 2009;11:123-132.
26. Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, et al. SHARPIN is a component of the NF- κ B-activating linear ubiquitin chain assembly complex. *Nature* 2011;471:633-636.
27. Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. *EMBO J* 2006;25:4877-4887.
28. Fiil BK, Gyrd-Hansen M. Met1-linked ubiquitination in immune signalling. *FEBS J.* 2014;281:4337-4350.
29. Iwai K. Diverse ubiquitin signaling in NF- κ B activation. *Trends Cell Biol.* 2012;22:355-364.
30. Iwai K, Fujita H, Sasaki Y. Linear ubiquitin chains: NF- κ B signalling, cell death and beyond. *Nat Rev Mol Cell Biol* 2014;15:503-508.
31. Boisson B, Laplantine E, Prando C, Giliani S, Israelsson E, Xu Z, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. *Nat Immunol* 2012;13:1178-1186.
32. Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. *Nat Med.* 2014;20:1242-1253.
33. Turner GC, Varshavsky A. Detecting and measuring cotranslational protein degradation in vivo. *Science.* 2000;289:2117-2120.
34. Peng J, Schwartz D, Elias JE, Thoreen CC, Cheng D, Marsischky G, et al. A proteomics approach to understanding protein ubiquitination. *Nature Biotechnology* 2003;21:921-926.
35. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, et al.

- 724 Linear ubiquitination prevents inflammation and regulates immune signalling. *Nature*
- 725 2011;471:591-596.
- 726 36. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, et al.
- 727 SHARPIN forms a linear ubiquitin ligase complex regulating NF- κ B activity and apoptosis.
- 728 *Nature* 2011;471:637-641.
- 729 37. Spratt DE, Walden H, Shaw GS. RBR E3 ubiquitin ligases: new structures, new
- 730 insights, new questions. *Biochem J* 2014;458:421-437.
- 731 38. Stieglitz B, Rana RR, Koliopoulos MG, Morris-Davies AC, Schaeffer V,
- 732 Christodoulou E, et al. Structural basis for ligase-specific conjugation of linear ubiquitin
- 733 chains by HOIP. *Nature* 2013;503:422-426.
- 734 39. Smit JJ, Monteferrario D, Noordermeer SM, van Dijk WJ, van der Reijden BA,
- 735 Sixma TK. The E3 ligase HOIP specifies linear ubiquitin chain assembly through its
- 736 RING-IBR-RING domain and the unique LDD extension. *EMBO J* 2012;31:3833-3844.
- 737 40. Yagi H, Ishimoto K, Hiromoto T, Fujita H, Mizushima T, Uekusa Y, et al. A
- 738 non-canonical UBA-UBL interaction forms the linear-ubiquitin-chain assembly complex.
- 739 *EMBO Rep* 2012;13:462-468.
- 740 41. Stieglitz B, Morris-Davies AC, Koliopoulos MG, Christodoulou E, Rittinger K.
- 741 LUBAC synthesizes linear ubiquitin chains via a thioester intermediate. *EMBO Rep*
- 742 2012;13:840-846.
- 743 42. Walczak H, Iwai K, Dikic I. Generation and physiological roles of linear
- 744 ubiquitin chains. *BMC Biol* 2012;10:23.
- 745 43. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of
- 746 ubiquitin-specific deubiquitinating enzymes. *Annu Rev Biochem* 2009;78:363-397.
- 747 44. Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S,
- 748 et al. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. *Mol*
- 749 *Cell*. 2013;50:818-830.
- 750 45. Keusekotten K, Elliott PR, Glockner L, Fiil BK, Damgaard RB, Kulathu Y, et al.
- 751 OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked
- 752 polyubiquitin. *Cell* 2013;153:1312-1326.
- 753 46. Takiuchi T, Nakagawa T, Tamiya H, Fujita H, Sasaki Y, Saeki Y, et al.

- 754 Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between
- 755 LUBAC and the deubiquitinases CYLD and OTULIN. *Genes Cells* 2014;19:254-272.
- 756 47. Datta AB, Hura GL, Wolberger C. The structure and conformation of
- 757 Lys63-linked tetraubiquitin. *J Mol Biol.* 2009;392(5):1117-24.
- 758 48. Rohaim A, Kawasaki M, Kato R, Dikic I, Wakatsuki S. Structure of a compact
- 759 conformation of linear diubiquitin. *Acta crystallographica Section D, Biological*
- 760 *Crystallography.* 2012;68(Pt 2):102-108.
- 761 49. Saggat S, Chernoff KA, Lodha S, Horev L, Kohl S, Honjo RS, et al. CYLD
- 762 mutations in familial skin appendage tumours. *J Medical Genet* 2008;45:298-302.
- 763 50. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF- κ B activation
- 764 and diverse biological processes. *Cell Death Differ* 2010;17:25-34.
- 765 51. Trompouki E, Hatzivassiliou E, Tschirritsis T, Farmer H, Ashworth A, Mosialos G.
- 766 CYLD is a deubiquitinating enzyme that negatively regulates NF- κ B activation by TNFR
- 767 family members. *Nature.* 2003;424:793-796.
- 768 52. Harhaj EW, Dixit VM. Regulation of NF- κ B by deubiquitinases. *Immunol Rev*
- 769 2012;246:107-124.
- 770 53. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits
- 771 tumor cell proliferation by blocking Bcl-3-dependent NF- κ B signaling. *Cell*
- 772 2006;125:665-677.
- 773 54. Sasaki Y, Sano S, Nakahara M, Murata S, Kometani K, Aiba Y, et al. Defective
- 774 immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells.
- 775 *EMBO J* 2013;32:2463-2476.
- 776 55. Peltzer N, Rieser E, Taraborrelli L, Draber P, Darding M, Pernaute B, et al. HOIP
- 777 deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death.
- 778 *Cell Reports* 2014;9:153-165.
- 779 56. HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher
- 780 C. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice.
- 781 *American J Pathol* 1993;143:972-982.
- 782 57. Gallardo Torres HI, Gijbels MJ, HogenEsch H, Kraal G. Chronic proliferative
- 783 dermatitis in mice: neutrophil-endothelium interactions and the role of adhesion molecules.

- 784 Pathobiology : Pathobiology 1995;63:341-347.
- 785 58. Gijbels MJ, Zurcher C, Kraal G, Elliott GR, HogenEsch H, Schijff G, et al.
- 786 Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm).
- 787 American J Pathol 1996;148:941-950.
- 788 59. Gijbels MJ, HogenEsch H, Blauw B, Roholl P, Zurcher C. Ultrastructure of
- 789 epidermis of mice with chronic proliferative dermatitis. Ultrastruct Pathol
- 790 1995;19:107-111.
- 791 60. Liang Y, Seymour RE, Sundberg JP. Inhibition of NF-kappaB signaling retards
- 792 eosinophilic dermatitis in SHARPIN-deficient mice. J Invest Dermatol. 2011;131:141-149.
- 793 61. Potter CS, Wang Z, Silva KA, Kennedy VE, Stearns TM, Burzenski L, et al.
- 794 Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory
- 795 disease in the absence of B and T lymphocytes and IL4/IL13 signaling. PLoS One
- 796 2014;9:e85666.
- 797 62. Seymour R, Sundberg JP, Hogenesch H. Abnormal lymphoid organ development
- 798 in immunodeficient mutant mice. Vet Pathol 2006;43:401-423.
- 799 63. HogenEsch H, Janke S, Boggess D, Sundberg JP. Absence of Peyer's patches and
- 800 abnormal lymphoid architecture in chronic proliferative dermatitis (cpdm/cpdm) mice. J
- 801 Immunol 1999;162:3890-3896.
- 802 64. Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M, et al.
- 803 Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key
- 804 regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014;192:5476-5480.
- 805 65. Rivkin E, Almeida SM, Ceccarelli DF, Juang YC, MacLean TA, Srikumar T, et al.
- 806 The linear ubiquitin-specific deubiquitinase gumbly regulates angiogenesis. Nature
- 807 2013;498:318-324.
- 808 66. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et al.
- 809 Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genet
- 810 2000;25:160-165.
- 811 67. Lee DA, Grossman ME, Schneiderman P, Celebi JT. Genetics of skin appendage
- 812 neoplasms and related syndromes. J Med Genet 2005;42(11):811-819.
- 813 68. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK.

- 814 Reduced expression of CYLD in human colon and hepatocellular carcinomas.
- 815 Carcinogenesis. 2007;28:21-27.
- 816 69. Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JM, et al. Impaired
- 817 regulation of NF- κ B and increased susceptibility to colitis-associated tumorigenesis in
- 818 CYLD-deficient mice. J Clin Invest. 2006;116:3042-3049.
- 819 70. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the
- 820 cylindromatosis tumour suppressor inhibits apoptosis by activating NF- κ B. Nature
- 821 2003;424:797-801.
- 822 71. Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I.
- 823 Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation,
- 824 fibrosis, and cancer. Cancer Cell 2012;21:738-750.
- 825 72. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, et al.
- 826 Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol
- 827 2011;13:1437-1442.
- 828 73. Xue L, Igaki T, Kuranaga E, Kanda H, Miura M, Xu T. Tumor suppressor CYLD
- 829 regulates JNK-induced cell death in Drosophila. Dev Cell 2007;13:446-454.
- 830 74. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M, et al. Regulation of
- 831 early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD.
- 832 Dev Cell 2007;13:705-716.
- 833 75. Wang L, Du F, Wang X. TNF- α induces two distinct caspase-8 activation
- 834 pathways. Cell 2008;133:693-703.
- 835 76. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al.
- 836 Mutations of multiple genes cause deregulation of NF- κ B in diffuse large B-cell lymphoma.
- 837 Nature 2009;459:717-721.
- 838 77. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κ B
- 839 activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
- 840 J Exp Med 2001;194:1861-1874.
- 841 78. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of
- 842 I κ B kinase activity through IKK β subunit phosphorylation. Science 1999;284:309-313.
- 843 79. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by

- 844 IKK α of a second, evolutionary conserved, NF- κ B signaling pathway. *Science*
- 845 2001;293:1495-1499.
- 846 80. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, et al. The IKK β
- 847 subunit of I κ B kinase (IKK) is essential for nuclear factor κ B activation and prevention of
- 848 apoptosis. *J Exp Med* 1999;189:1839-1845.
- 849 81. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK- γ is an essential regulatory
- 850 subunit of the I κ B kinase complex. *Nature* 1998;395:297-300.
- 851 82. Heissmeyer V, Krappmann D, Hatada EN, Scheidereit C. Shared pathways of I κ B
- 852 kinase-induced SCF(β TrCP)-mediated ubiquitination and degradation for the NF- κ B
- 853 precursor p105 and I κ B α . *Mol Cell Biol* 2001;21:1024-1035.
- 854 83. Shirane M, Hatakeyama S, Hattori K, Nakayama K, Nakayama K. Common
- 855 pathway for the ubiquitination of I κ B α , I κ B β , and I κ B ϵ mediated by the F-box protein
- 856 FWD1. *J Biol Chem* 1999;274:28169-28174.
- 857 84. Hatakeyama S, Kitagawa M, Nakayama K, Shirane M, Matsumoto M, Hattori K,
- 858 et al. Ubiquitin-dependent degradation of I κ B α is mediated by a ubiquitin ligase Skp1/Cul
- 859 1/F-box protein FWD1. *Proc Natl Acad Sci U S A* 1999;96:3859-3863.
- 860 85. Wu C, Ghosh S. β -TrCP mediates the signal-induced ubiquitination of I κ B β . *J*
- 861 *Biol Chem* 1999;274(42):29591-29594.
- 862 86. Smit JJ, van Dijk WJ, El Atmioui D, Merks R, Ovaa H, Sixma TK. Target
- 863 specificity of the E3 ligase LUBAC for ubiquitin and NEMO relies on different minimal
- 864 requirements. *J Biol Chem*. 2013;288:31728-31737.
- 865 87. Rahighi S, Ikeda F, Kawasaki M, Akutsu M, Suzuki N, Kato R, et al. Specific
- 866 recognition of linear ubiquitin chains by NEMO is important for NF- κ B activation. *Cell*
- 867 2009;136:1098-1109.
- 868 88. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD,
- 869 Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear
- 870 polyubiquitin chains. *EMBO Rep* 2009;10:466-473.
- 871 89. Fujita H, Rahighi S, Akita M, Kato R, Sasaki Y, Wakatsuki S, et al. Mechanism
- 872 underlying I κ B kinase activation mediated by the linear ubiquitin chain assembly complex.
- 873 *Mol Cell Biol* 2014;34:1322-1335.

- 874 90. Elliott PR, Nielsen SV, Marco-Casanova P, Fiil BK, Keusekotten K, Mailand N,
875 et al. Molecular basis and regulation of OTULIN-LUBAC interaction. *Mol Cell*
876 2014;54:335-348.
- 877 91. Schaeffer V, Akutsu M, Olma MH, Gomes LC, Kawasaki M, Dikic I. Binding of
878 OTULIN to the PUB domain of HOIP controls NF- κ B signaling. *Mol Cell*
879 2014;54:349-361.
- 880 92. Tokunaga F, Nishimasu H, Ishitani R, Goto E, Noguchi T, Mio K, et al. Specific
881 recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF- κ B regulation.
882 *EMBO J* 2012;31:3856-3870.
- 883 93. Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T, et al.
884 A20 inhibits LUBAC-mediated NF- κ B activation by binding linear polyubiquitin chains
885 via its zinc finger 7. *EMBO J* 2012;31:3845-3855.
- 886 94. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al. The
887 ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.
888 *Nat Immunol* 2004;5:1052-1060.
- 889 95. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, et al.
890 De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF- κ B signalling.
891 *Nature* 2004;430:694-699.
- 892 96. Tokunaga F. Linear ubiquitination-mediated NF- κ B regulation and its related
893 disorders. *J Biochem.* 2013;154:313-323.
- 894 97. Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, et al. The
895 ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate
896 immunity. *Mol Cell* 2012;46:746-758.
- 897 98. Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, et
898 al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune
899 signalling. *EMBO molecular medicine.* 2013;5(8):1278-1295.
- 900 99. Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC.
901 Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked
902 polyubiquitin chains. *Mol Cell Biol* 2007;27:6012-6025.
- 903 100. Deguine J, Barton GM. MyD88: a central player in innate immune signaling.

- 904 F1000prime Reports 2014;6:97.
- 905 101. Takeuchi O, Akira S. MyD88 as a bottle neck in Toll/IL-1 signaling. *Curr Top*
- 906 *Microbiol Immunol* 2002;270:155-167.
- 907 102. Dubois SM, Alexia C, Wu Y, Leclair HM, Leveau C, Schol E, et al. A
- 908 catalytic-independent role for the LUBAC in NF- κ B activation upon antigen receptor
- 909 engagement and in lymphoma cells. *Blood* 2014;123:2199-2203.
- 910 103. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al. Activation of the I κ B
- 911 kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a
- 912 unique polyubiquitin chain. *Cell* 2000;103:351-361.
- 913 104. Wertz IE, Dixit VM. Signaling to NF- κ B: regulation by ubiquitination. *Cold*
- 914 *Spring Harbor perspectives in biology*. 2010;2:a003350.
- 915 105. Emmerich CH, Ordureau A, Strickson S, Arthur JS, Pedrioli PG, Komander D, et
- 916 al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains.
- 917 *Proc Natl Acad Sci U S A*. 2013;110:15247-15252.
- 918 106. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF- κ B regulatory pathways.
- 919 *Annu Rev Biochem* 2009;78:769-796.
- 920 107. Gantke T, Sriskantharajah S, Sadowski M, Ley SC. I κ B kinase regulation of
- 921 the TPL-2/ERK MAPK pathway. *Immunological reviews*. 2012;246(1):168-82.
- 922 108. Roget K, Ben-Addi A, Mambole-Dema A, Gantke T, Yang HT, Janzen J, et al.
- 923 I κ B kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by
- 924 direct phosphorylation of TPL-2 serine 400. *Mol Cell Biol* 2012;32:4684-4690.
- 925 109. Kumari S, Redouane Y, Lopez-Mosqueda J, Shiraishi R, Romanowska M,
- 926 Lutzmayer S, et al. Sharpin prevents skin inflammation by inhibiting TNFR1-induced
- 927 keratinocyte apoptosis. *Elife*. 2014;3.
- 928 110. Rickard JA, Anderton H, Etemadi N, Nachbur U, Darding M, Peltzer N, et al.
- 929 TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. *Elife*. 2014;3.
- 930 111. Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to
- 931 activate TNF receptor 1. *Cell Cycle*. 2003;2:550-552.
- 932 112. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors.
- 933 *Cell Signal*. 2012;24:1297-1305.

- 934 113. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al.
935 Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1
936 signaling complex and is required for TNF-mediated gene induction. *Mol Cell*
937 2009;36:831-844.
- 938 114. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L,
939 et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling.
940 *EMBO J* 2010;29:4198-4209.
- 941 115. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al.
942 Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed
943 necrosis and virus-induced inflammation. *Cell* 2009;137:1112-1123.
- 944 116. He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting protein
945 kinase-3 determines cellular necrotic response to TNF- α . *Cell*. 2009;137:1100-1111.
- 946 117. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, et al. RIP3, an energy
947 metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis.
948 *Science* 2009;325:332-336.
- 949 118. Lu TT, Onizawa M, Hammer GE, Turer EE, Yin Q, Damko E, et al. Dimerization
950 and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. *Immunity*
951 2013;38:896-905.
- 952 119. Shembade N, Ma A, Harhaj EW. Inhibition of NF- κ B signaling by A20 through
953 disruption of ubiquitin enzyme complexes. *Science* 2010;327:1135-1139.
- 954 120. Wu P, Shi KJ, An JJ, Ci YL, Li F, Hui KY, et al. The LEF1/CYLD axis and cIAPs
955 regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer
956 cells. *Cell Death Dis* 2014;5:e1085.
- 957 121. Mocarski ES, Upton JW, Kaiser WJ. Viral infection and the evolution of caspase
958 8-regulated apoptotic and necrotic death pathways. *Nature Rev Immunol* 2012;12:79-88.
- 959 122. Chen I, Ichinohe T. Response of host inflammasomes to viral infection. *Trends in*
960 *microbiology*. 2015;23(1):55-63.
- 961 123. Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated
962 inflammasome activation. *Immunity*. 2013;39:432-441.
- 963 124. Rodgers MA, Bowman JW, Fujita H, Orazio N, Shi M, Liang Q, et al. The linear

- ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. *J Exp Med* 2014;211:1333-1347.
125. Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T. Viral RNA detection by RIG-I-like receptors. *Curr Opin Immunol* 2015;32C:48-53.
126. Paz S, Vilasco M, Werden SJ, Arguello M, Joseph-Pillai D, Zhao T, et al. A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response. *Cell Res* 2011;21:895-910.
127. Belgnaoui SM, Paz S, Samuel S, Goulet ML, Sun Q, Kikkert M, et al. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. *Cell Host Microbe* 2012;12:211-222.
128. Liu S, Chen J, Cai X, Wu J, Chen X, Wu YT, et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. *Elife*. 2013;2:e00785.
129. Inn KS, Gack MU, Tokunaga F, Shi M, Wong LY, Iwai K, et al. Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. *Mol Cell* 2011;41:354-365.
130. Zhao S, Ulrich HD. Distinct consequences of posttranslational modification by linear versus K63-linked polyubiquitin chains. *Proc Natl Acad Sci U S A* 2010;107:7704-7709.
131. Pouwels J, De Franceschi N, Rantakari P, Auvinen K, Karikoski M, Mattila E, et al. SHARPIN regulates uropod detachment in migrating lymphocytes. *Cell Reports* 2013;5:619-628.
132. Rantala JK, Pouwels J, Pellinen T, Veltel S, Laasola P, Mattila E, et al. SHARPIN is an endogenous inhibitor of beta1-integrin activation. *Nat Cell Biol* 2011;13:1315-1324.
133. Queisser MA, Dada LA, Deiss-Yehiely N, Angulo M, Zhou G, Kouri FM, et al. HOIL-1L Functions as the PKC ζ Ubiquitin Ligase to Promote Lung Tumor Growth. *Am J Respir Crit Care Med* 2014;190:688-698.
134. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. *Nature* 2015;517:311-320.
135. Davidovich P, Kearney CJ, Martin SJ. Inflammatory outcomes of apoptosis, necrosis and necroptosis. *Biol Chem* 2014;395:1163-1171.

- 994 136. Tamiya H, Terao M, Takiuchi T, Nakahara M, Sasaki Y, Katayama I, et al. IFN- γ
995 or IFN- α ameliorates chronic proliferative dermatitis by inducing expression of linear
996 ubiquitin chain assembly complex. *J Immunol* 2014;192:3793-3804.
- 997 137. Baeuerle PA, Henkel T. Function and activation of NF- κ B in the immune system.
998 *Ann Rev Immunol* 1994;12:141-179.
- 999 138. Lam KP, Rajewsky K. B cell antigen receptor specificity and surface density
1000 together determine B-1 versus B-2 cell development. *J Exp Med* 1999;190:471-477.
- 1001 139. Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, et al. Essential role
1002 of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline
1003 polymorphisms. *Cancer Discov* 2014;4:480-493.
- 1004 140. Nilsson J, Schoser B, Laforet P, Kalev O, Lindberg C, Romero NB, et al.
1005 Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1. *Annals*
1006 *Neurol* 2013;74:914-919.
- 1007 141. Wang K, Kim C, Bradfield J, Guo Y, Toskala E, Otieno FG, et al. Whole-genome
1008 DNA/RNA sequencing identifies truncating mutations in RBCK1 in a novel Mendelian
1009 disease with neuromuscular and cardiac involvement. *Genome Med* 2013;5:67.
- 1010 142. MacDuff DA, Reese TA, Kimmey JM, Weiss LA, Song C, Zhang X, et al.
1011 Phenotypic complementation of genetic immunodeficiency by chronic herpesvirus infection.
1012 *Elife*. 2015;4.
- 1013 143. Tomonaga M, Hashimoto N, Tokunaga F, Onishi M, Myoui A, Yoshikawa H, et al.
1014 Activation of nuclear factor- κ B by linear ubiquitin chain assembly complex contributes to
1015 lung metastasis of osteosarcoma cells. *Int J Oncol* 2012;40:409-417.
- 1016 144. Mackay C, Carroll E, Ibrahim AF, Garg A, Inman GJ, Hay RT, et al. E3 ubiquitin
1017 ligase HOIP attenuates apoptotic cell death induced by cisplatin. *Cancer Res*
1018 2014;74:2246-2257.
- 1019 145. Sakamoto H, Egashira S, Saito N, Kirisako T, Miller S, Sasaki Y, et al. Gliotoxin
1020 Suppresses NF- κ B Activation by Selectively Inhibiting Linear Ubiquitin Chain Assembly
1021 Complex (LUBAC). *ACS Chem Biol*. 2014.
- 1022 146. Wild P, Farhan H, McEwan DG, Wagner S, Rogov VV, Brady NR, et al.
1023 Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. *Science*

- 1
- 2
- 3
- 4
- 5
- 6 1024 2011;333:228-233.
- 7
- 8 1025 147. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of
- 9 1026 optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223-226.
- 10
- 11 1027 148. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al.
- 12 1028 Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science
- 13 1029 2002;295:1077-1079.
- 14
- 15
- 16
- 17 1030
- 18
- 19 1031
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For Review Only

1032 **Figure legends**

1033

1034 **Figure 1. The ubiquitin conjugating system and ubiquitin chain lineage-specific** 1035 **behavior.**

1036 Ubiquitylation is an enzymatic process mediated by a ubiquitin activating enzyme (E1), a
1037 ubiquitin conjugating enzyme (ubiquitin carrier protein) (E2), and a ubiquitin ligase (E3).
1038 First, ubiquitin is ATP-dependently transferred to E1 via formation of a thioester bond
1039 between the C-terminal carboxyl group of ubiquitin and the cysteine residue in the active
1040 site of E1. Ubiquitin on the E1 is then transferred to the cysteine residue of E2, which also
1041 forms a thioester bond. Finally, E3 associates with the ubiquitin-bound E2 and a substrate,
1042 and catalyzes the conjugation of ubiquitin to the substrate via an isopeptide bond between
1043 the ϵ -amino group of a lysine residue of the substrate and the C-terminal carboxyl group of
1044 ubiquitin. There are three classes of E3s: HECT, RING, and RBR E3s. HECT and RBR E3s
1045 bind to ubiquitin before conjugating ubiquitin to substrates, as described in Figure 3. Once
1046 the first ubiquitin is conjugated to the substrate, additional ubiquitins are conjugated
1047 successively onto the terminal ubiquitin on the substrate to form polyubiquitin chains.
1048 Polyubiquitin chains are generated by isopeptide bond formation between the C-terminal
1049 carboxyl group of one ubiquitin and an ϵ -amino group of one of seven Lys (K) residues in
1050 another ubiquitin molecule, thus generating seven types (K6, K11, K27, K29, K33 aK48,
1051 and K63) of linkages. A linear (M1) linkage, in which the C-terminal carboxyl group of one

ubiquitin forms a peptide bond with an α -amino group of the N-terminal Met (M) residue of another ubiquitin, was reported. Four types of polyubiquitin chains [K11-linked, K48-linked, K63-linked, and Linear (M1-linked)] are shown. Each chain is recognized by ubiquitin binding proteins containing a specific ubiquitin binding domain (UBD). The polyubiquitin chains are cleaved by deubiquitinating enzymes (DUB). DUBs can be specific for certain types of ubiquitin linkage. Ubiquitin monomers newly-trimmed by DUBs are integrated into the ubiquitin pool to be used for further ubiquitination of other proteins.

Figure 2. Schematic representation of LUBAC components.

The linear ubiquitin chain assembly complex (LUBAC) is composed of heme-oxidized IRP2 ligase 1L (HOIL-1L), HOIL-1 interacting protein (HOIP), and SH3 and multiple ankyrin-repeat domains protein (SHANK)-associated RBCK1 homology (RH) domain-interacting protein (SHARPIN). Arrows indicate protein-protein interactions to form LUBAC's ternary structure. Interactions between the HOIP NZF2 and SHARPIN UBL are also involved in LUBAC formation; however, HOIP lacking NZF2, and not UBA, binds to SHARPIN in cells. HOIP contains the catalytic center for ubiquitin E3 ligase activity in its carboxyl-terminal region. UBL, ubiquitin-like domain; UBA, ubiquitin-associated domain; NZF, nuclear protein localization 4(Npl4)-type zinc finger; RING, really interesting new gene; IBR, in-between-RING domain; ZF, zinc finger; PUB,

1072 peptide N-glycosidase (PNGase)/ubiquitin-associated domain; LDD, linear ubiquitin chain

1073 determining domain.

1074

1075 **Figure 3. Different ubiquitin conjugation modes mediated by three E3 ligase families.**

1076 A. Homology to E6-AP C-terminus (HECT) E3 ligases forms an intermediate complex via

1077 a thioester bond between a cysteine residue of E3s and the C-terminus of ubiquitin

1078 activated by E2 before transfer to the substrate. B. Really Interesting New Gene (RING) E3

1079 ligases catalyze the conjugation of ubiquitin from E2 to the substrate directly. C. The

1080 RING-In-Between-RING (IBR)-RING (RBR) E3 ligase family, to which LUBAC belongs,

1081 uses the hybrid ubiquitin conjugation mechanism of the RING and the HECT E3s. In this

1082 mechanism, the RING2 domain of RBR E3s binds to the C-terminus of ubiquitin to form

1083 an intermediate, as seen in a RING-like manner after the binding of ubiquitin-conjugated

1084 E2 to the RING1 domain of the RBR E3s. The activated ubiquitin on the RING2 domain is

1085 subsequently transferred to a substrate in a HECT-like manner.

1086

1087 **Figure 4. LUBAC-mediated linear ubiquitylation in the canonical NF- κ B activation** 1088 **pathway.**

1089 The contribution of LUBAC to the tumor necrosis factor (TNF)- α -induced activation of

1090 nuclear factor-kappa B (NF- κ B) pathway is well-established. TNF- α engagement to TNF

1091 receptor 1 (TNFR1) allows its conformational change resulting in the recruitment of RIP1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1092 and TRADD via homotypic interactions between two death domains; TRAF2 and cellular
1093 inhibitor of apoptosis proteins (cIAPs) are also incorporated into the TNFR1 complex.
1094 RIP1 is often detected as a ubiquitin-conjugated protein after TNF- α stimulation. The E3
1095 ligases, cIAPs, ubiquitinate components of the activated TNFR1 complex, including RIP1,
1096 with K63 and K11-linked ubiquitin chains, and themselves by auto-ubiquitination. These
1097 generated ubiquitin chains on components of the TNFR1 complex were suggested to serve
1098 as a platform to recruit the TAK1 complex, which is composed of TAK1, TAB1, and TAB2
1099 and/or TAB3, and the recruitment of TAK1 facilitates the phosphorylation of IKK2
1100 necessary for the activation of the IKK complex. LUBAC is recruited to the ubiquitin
1101 chains within the TNFR1 complex via the K63 (possibly also K11) ubiquitin chain-binding
1102 property of the NZF1 domain of HOIP. The HOIP NZF1 domain can interact with NEMO
1103 in the IKK complex in addition to ubiquitin chains, and conjugate the linear ubiquitin chain
1104 on NEMO. The linear ubiquitin chain conjugated to NEMO recruits another IKK complex
1105 because NEMO contains a specific binding region for linear ubiquitin chains called the
1106 ubiquitin binding in ABIN and NEMO (UBAN) motif, which triggers dimerization of IKK
1107 complexes and subsequent trans-autophosphorylation of IKK2. The activated IKK complex
1108 phosphorylates I κ B α , leading to its K48-linked ubiquitination and proteasomal degradation.
1109 This process activates the cytosolic NF- κ B transcription factor, facilitating its translocation
1110 to the nucleus and the induction of the expression of target genes.
1111

1112 **Figure 5. Inhibition of TNF- α mediated cell death by linear ubiquitylation**

1113 Upon binding TNF- α , TNFR1 interacts with TRADD, RIP1, TRAF2, and cIAP1 and 2 to
1114 form complex I. LUBAC is also recruited to the activated TNFR1 complex via recognition
1115 of ubiquitin chains in the TNFR1 complex possibly by cIAP1 and 2. LUBAC protects cells
1116 from death by inducing the expression of various NF- κ B target genes, including Bcl-2 and
1117 cFLIP. In addition to the induction of anti-apoptotic genes, LUBAC inhibits
1118 TNF- α -mediated cell death by a different mechanism, the inhibition of complex II. The
1119 transition from complex I to complex II triggers cell death. TNFR1 induces two types of
1120 programmed cell death, apoptosis and necroptosis, and formation of complex II, which is
1121 composed of TRADD, FADD, caspase 8, RIP1, and possibly RIP3, precedes both types of
1122 cell death. After the formation of complex II, caspase 8 is activated by dimerization and
1123 digests RIP1 and RIP3, leading to apoptosis. When caspase 8 is inactivated, RIP1 and RIP3
1124 kinases are activated and trigger necroptosis. The linear ubiquitination activity of LUBAC
1125 is involved in the suppression of complex II formation, although the linear ubiquitylation
1126 substrates involved in the inhibition of complex II formation have not been convincingly
1127 identified to date.

Figure 1. The ubiquitin conjugating system and ubiquitin chain lineage-specific behavior. Ubiquitylation is an enzymatic process mediated by a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme (ubiquitin carrier protein) (E2), and a ubiquitin ligase (E3). First, ubiquitin is ATP-dependently transferred to E1 via formation of a thioester bond between the C-terminal carboxyl group of ubiquitin and the cysteine residue in the active site of E1. Ubiquitin on the E1 is then transferred to the cysteine residue of E2, which also forms a thioester bond. Finally, E3 associates with the ubiquitin-bound E2 and a substrate, and catalyzes the conjugation of ubiquitin to the substrate via an isopeptide bond between the ϵ -amino group of a lysine residue of the substrate and the C-terminal carboxyl group of ubiquitin. There are three classes of E3s: HECT, RING, and RBR E3s. HECT and RBR E3s bind to ubiquitin before conjugating ubiquitin to substrates, as described in Figure 3. Once the first ubiquitin is conjugated to the substrate, additional ubiquitins are conjugated successively onto the terminal ubiquitin on the substrate to form polyubiquitin chains. Polyubiquitin chains are generated by isopeptide bond formation between the C-terminal carboxyl group of one ubiquitin and an ϵ -amino group of one of seven Lys (K) residues in another ubiquitin molecule, thus generating seven types (K6, K11, K27, K29, K33, K48, and K63) of linkages. A linear (M1) linkage, in which the C-terminal carboxyl group of one ubiquitin forms a peptide bond with an α -amino group of the N-terminal Met (M) residue of another ubiquitin, was reported. Four types of polyubiquitin chains [K11-linked, K48-linked, K63-linked, and Linear (M1-linked)] are shown. Each chain is recognized by ubiquitin binding proteins containing a specific ubiquitin binding domain (UBD). The polyubiquitin chains are cleaved by deubiquitinating enzymes (DUB). DUBs can be specific for certain types of ubiquitin linkage. Ubiquitin monomers newly-trimmed by DUBs are integrated into the ubiquitin pool to be used for further ubiquitination of other proteins.

677x508mm (72 x 72 DPI)

Figure 2. Schematic representation of LUBAC components.

The linear ubiquitin chain assembly complex (LUBAC) is composed of heme-oxidized IRP2 ligase 1L (HOIL-1L), HOIL-1 interacting protein (HOIP), and SH3 and multiple ankyrin-repeat domains protein (SHANK)-associated RBCK1 homology (RH) domain-interacting protein (SHARPIN). Arrows indicate protein-protein interactions to form LUBAC's ternary structure. Interactions between the HOIP NZF2 and SHARPIN UBL are also involved in LUBAC formation; however, HOIP lacking NZF2, and not UBA, binds to SHARPIN in cells.

HOIP contains the catalytic center for ubiquitin E3 ligase activity in its carboxyl-terminal region. UBL, ubiquitin-like domain; UBA, ubiquitin-associated domain; NZF, nuclear protein localization 4(Npl4)-type zinc finger; RING, really interesting new gene; IBR, in-between-RING domain; ZF, zinc finger; PUB, peptide N-glycosidase (PNGase)/ubiquitin-associated domain; LDD, linear ubiquitin chain determining domain.

677x508mm (72 x 72 DPI)

Figure 3. Different ubiquitin conjugation modes mediated by three E3 ligase families.
A. Homology to E6-AP C-terminus (HECT) E3 ligases forms an intermediate complex via a thioester bond between a cysteine residue of E3s and the C-terminus of ubiquitin activated by E2 before transfer to the substrate. B. Really Interesting New Gene (RING) E3 ligases catalyze the conjugation of ubiquitin from E2 to the substrate directly. C. The RING-In-Between-RING (IBR)-RING (RBR) E3 ligase family, to which LUBAC belongs, uses the hybrid ubiquitin conjugation mechanism of the RING and the HECT E3s. In this mechanism, the RING2 domain of RBR E3s binds to the C-terminus of ubiquitin to form an intermediate, as seen in a RING-like manner after the binding of ubiquitin-conjugated E2 to the RING1 domain of the RBR E3s. The activated ubiquitin on the RING2 domain is subsequently transferred to a substrate in a HECT-like manner.

677x508mm (72 x 72 DPI)

Figure 4. LUBAC-mediated linear ubiquitinylation in the canonical NF- κ B activation pathway. The contribution of LUBAC to the tumor necrosis factor (TNF)- α -induced activation of nuclear factor-kappa B (NF- κ B) pathway is well-established. TNF- α engagement to TNF receptor 1 (TNFR1) allows its conformational change resulting in the recruitment of RIP1 and TRADD via homotypic interactions between two death domains; TRAF2 and cellular inhibitor of apoptosis proteins (cIAPs) are also incorporated into the TNFR1 complex. RIP1 is often detected as a ubiquitin-conjugated protein after TNF- α stimulation. The E3 ligases, cIAPs, ubiquitinate components of the activated TNFR1 complex, including RIP1, with K63 and K11-linked ubiquitin chains, and themselves by auto-ubiquitination. These generated ubiquitin chains on components of the TNFR1 complex were suggested to serve as a platform to recruit the TAK1 complex, which is composed of TAK1, TAB1, and TAB2 and/or TAB3, and the recruitment of TAK1 facilitates the phosphorylation of IKK2 necessary for the activation of the IKK complex. LUBAC is recruited to the ubiquitin chains within the TNFR1 complex via the K63 (possibly also K11) ubiquitin chain-binding property of the NZF1 domain of HOIP. The HOIP NZF1 domain can interact with NEMO in the IKK complex in addition to ubiquitin chains, and conjugate the linear ubiquitin chain on NEMO. The linear ubiquitin chain conjugated to NEMO recruits another IKK complex because NEMO contains a specific binding region for linear ubiquitin chains called the ubiquitin binding in ABIN and NEMO (UBAN) motif, which triggers dimerization of IKK complexes and subsequent trans-autophosphorylation of IKK2. The activated IKK complex phosphorylates I κ B α , leading to its K48-linked ubiquitination and proteasomal degradation. This process activates the cytosolic NF- κ B transcription factor, facilitating its translocation to the nucleus and the induction of the expression of target genes.

677x508mm (72 x 72 DPI)

Figure 5. Inhibition of TNF-α mediated cell death by linear ubiquitinylation

Upon binding TNF-α, TNFR1 interacts with TRADD, RIP1, TRAF2, and cIAP1 and 2 to form complex I. LUBAC is also recruited to the activated TNFR1 complex via recognition of ubiquitin chains in the TNFR1 complex possibly by cIAP1 and 2. LUBAC protects cells from death by inducing the expression of various NF-κB target genes, including Bcl-2 and cFLIP. In addition to the induction of anti-apoptotic genes, LUBAC inhibits TNF-α-mediated cell death by a different mechanism, the inhibition of complex II. The transition from complex I to complex II triggers cell death. TNFR1 induces two types of programmed cell death, apoptosis and necroptosis, and formation of complex II, which is composed of TRADD, FADD, caspase 8, RIP1, and possibly RIP3, precedes both types of cell death. After the formation of complex II, caspase 8 is activated by dimerization and digests RIP1 and RIP3, leading to apoptosis. When caspase 8 is inactivated, RIP1 and RIP3 kinases are activated and trigger necroptosis. The linear ubiquitination activity of LUBAC is involved in the suppression of complex II formation, although the linear ubiquitinylation substrates involved in the inhibition of complex II formation have not been convincingly identified to date.

677x508mm (72 x 72 DPI)